US20050118152A1 - Analytical method for detecting alkaline sphingomyelinase and kit for use in such method - Google Patents
Analytical method for detecting alkaline sphingomyelinase and kit for use in such method Download PDFInfo
- Publication number
- US20050118152A1 US20050118152A1 US10/499,336 US49933604A US2005118152A1 US 20050118152 A1 US20050118152 A1 US 20050118152A1 US 49933604 A US49933604 A US 49933604A US 2005118152 A1 US2005118152 A1 US 2005118152A1
- Authority
- US
- United States
- Prior art keywords
- sample
- sphingomyelinase
- alkaline
- fluorescence
- sphingomyelin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 102100036093 Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Human genes 0.000 title claims abstract description 13
- 101000876377 Homo sapiens Ectonucleotide pyrophosphatase/phosphodiesterase family member 7 Proteins 0.000 title claims abstract description 13
- 238000004458 analytical method Methods 0.000 title description 4
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims abstract description 8
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims abstract description 8
- 239000003550 marker Substances 0.000 claims abstract description 5
- 101710124951 Phospholipase C Proteins 0.000 claims description 36
- 101710166827 Sphingomyelinase Proteins 0.000 claims description 36
- 101710122751 Sphingomyelinase C Proteins 0.000 claims description 36
- 239000000523 sample Substances 0.000 claims description 22
- 239000013060 biological fluid Substances 0.000 claims description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 11
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000012131 assay buffer Substances 0.000 claims description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 108010000659 Choline oxidase Proteins 0.000 claims description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 7
- 239000003833 bile salt Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 7
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007983 Tris buffer Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 229960001231 choline Drugs 0.000 claims description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 229940093761 bile salts Drugs 0.000 claims description 5
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 5
- 239000011539 homogenization buffer Substances 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 229950004354 phosphorylcholine Drugs 0.000 claims description 5
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims description 5
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 5
- 239000007836 KH2PO4 Substances 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 230000005284 excitation Effects 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 239000011535 reaction buffer Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 3
- 239000012888 bovine serum Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 238000002731 protein assay Methods 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 abstract description 4
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 108040005466 neutral sphingomyelin phosphodiesterase activity proteins Proteins 0.000 description 4
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 3
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 3
- 108010007979 Glycocholic Acid Proteins 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 3
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 3
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Definitions
- the present invention relates to an analytical method for assessing the presence of alkaline sphingomyelinase in the stools or biological fluids of patients in need of such an assessment.
- the invention also relates to a kit for carrying out the analytical method.
- the method of the present invention is an in vitro fluorometric method for detecting alkaline sphingomyelinase which, as will be described in detail hereinbelow, is a marker of serious pathological states such as colon cancer and familial adenomatous polyposis.
- sphingomyelinase sphingomyelin phosphodiesterase, SMase catalyzes the hydrolysis of sphingomyelin to ceramide and choline phosphate.
- SMases have been shown to play a role in a wide variety of physiologic and pathological processes, including: lysosomal hydrolysis of endocytosed SM, ceramide mediated cell signalling, atherogenesis, terminal differentiation, cell cycles arrest, apoptosis, inflammation, and the regulation of eukaryotic stress responses.
- alkaline SMase In contrast to acidic and neutral SMase, which are currently present in cells as lysosomal and membrane-bound enzymes, respectively, alkaline SMase exhibits tissue and species difference. In human beings, the alkaline SMase is found in intestinal mucosa and bile. Alkaline SMase starts to appear in the duodenum, reaches a high level in the intestine, especially in the distal part of the jejunum, and occurs in considerable amounts in the colon and rectum. This SMase presents optimal alkaline pH at 9.0, is Mg 2+ -independent, bile salt-dependent and trypsin-resistant.
- alkaline SMase The pathological importance of alkaline SMase has only recently been recognized and this has prompted several studies to be carried out, mainly for the following reasons.
- the enzyme may be responsible for the hydrolysis of the dietary sphingomyelin occurring substantially in milk, eggs, meat and fish.
- this enzyme may regulate cholesterol absorption.
- the presence of alkaline SMase along the intestinal tract and its selective decrease detected in colorectal carcinoma suggests that this enzyme plays a role in intestinal carcinogenesis, since under physiological conditions, it stimulates apoptosis and protects the intestinal mucosa against carcinogenesis.
- alkaline SMase is dissociated by bile salts from intestinal mucosal membrane to the lumen.
- bile salt concentration is abnormally increased
- the dissociation of alkaline SMase by bile salts may exceed the biosynthesis of the enzyme, resulting in a low level of activity of alkaline SMase in the mucosa, and an abnormally increased excretion of the enzyme in the faeces or in biological fluids, i.e. bile.
- alkaline SMase excreted in the stools or in biological fluids over normal, basal values, may be interpreted as a valuable diagnostic marker for colon rectal carcinoma and familial adenomatous polyposis, hence; the need of a reliable assay for detecting alkaline SMase in the stools or in biological fluids of patients likely to be suffering from the aforesaid pathologies of the intestinal tract.
- bacteria strains e.g. Streptococcus termophilus Lactobacilli
- the assessment of alkaline SMase may provide a method to evaluate changes in the number of said bacteria, i.e. after a treatment with probiotics or/and probiotic-based products.
- SMases Previous methods for assaying alkaline SMase are already known.
- the activity of the SMases can be determined either in vivo through cell labelled with a radioactive precursor of SM and then determining the labelling product levels or in vitro using radiolabelled SM or a chromogenic analog of SM or colored and fluorescent derivatives of neutral SM.
- An object of the present invention is to provide a reliable, unexpensive assay for alkaline SMase in the stools or biological fluids of patients likely to suffer from colorectal carcinoma and familial adenomatous polyposis, or gall bladder or liver diseases, which overcomes the drawbacks of the known methods.
- a further object of the present invention is to provide an analytical kit for use in the aforesaid assay.
- Another object of the present invention is the assessment of bacterial colonization in different health conditions or following diseases or treatment with drugs or probiotics or food supplements.
- the fluorometric, indirect assay method of the present invention is grounded on the following sequence of reactions.
- sphingomyelin Under the action of alkaline SMase, present in faeces or other biological fluids, sphingomyelin is hydrolyzed to ceramide and phosphorylcholine which, under the action of alkaline phosphatase, is hydrolyzed yelding choline. In the presence of choline oxidase, choline produces hydrogen peroxide (H 2 O 2 ).
- This latter compound in the presence of horse-radish peroxidase, is caused to react with 10-acetyl-3.7-dihidroxyphenoxazine, a sensitive fluorogenic probe for H 2 O 2 (hereinbelow referred to as “Amplex Red Reagent”) yelding the highly fluorescent compound resorufin. Fluorescence is measured with a fluorocount microplate fluorometer using excitation at 530-560 nm and fluorescence detection at 590 nm.
- the assay method of the present invention for assaying alcaline SMase comprises the following steps which refers to stools.
- this method can be easily applied also to biological fluids such as bile with appropriate routine variations,
- the invention also relates to a kit for detecting alkaline sphingomyelinase in a patient's stools or biological fluids according to the previously disclosed method, which comprises test tubes separately containing samples of the following reagents:
- the kit is supplied with a standard preparation of SMase, it consists of bacterial extract containing a type of SMase that works at pH 9. The following operations should be performed.
- FIG. 1 the standard curve is shown for demonstration only. A standard curve should be generated for each set of samples assayed.
- the described method is able to assay SMase activity in vitro; it has been developed with the intent to detect alkaline SMase in an organic sample.
- the method uses conditions that detect the acid and neutral SMases activity. In fact:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
An analytical fluorometric method and a kit for use in such method are disclosed for assessing the presence of alkaline sphingomyelinase (SMase) in the stools of a patient in need of such an assessment since alkaline SMase is a marker of serious pathological states, such as colon cancer.
Description
- The present invention relates to an analytical method for assessing the presence of alkaline sphingomyelinase in the stools or biological fluids of patients in need of such an assessment. The invention also relates to a kit for carrying out the analytical method.
- More particularly the method of the present invention is an in vitro fluorometric method for detecting alkaline sphingomyelinase which, as will be described in detail hereinbelow, is a marker of serious pathological states such as colon cancer and familial adenomatous polyposis.
- The enzyme sphingomyelinase (sphingomyelin phosphodiesterase, SMase) catalyzes the hydrolysis of sphingomyelin to ceramide and choline phosphate.
- Three different types of SMase (acidic, neutral and alkaline) have been identified to-date, which occur as several iso-forms, as follows:
-
- lysosomal acidic SMase (A-SMase);
- cytosolic Zn2+-dependent acidic SMase;
- membrane neutral magnesium-dependent SMase (N-SMase);
- cytosolic magnesium-independent N-SMase; and
- alkaline SMase.
- SMases have been shown to play a role in a wide variety of physiologic and pathological processes, including: lysosomal hydrolysis of endocytosed SM, ceramide mediated cell signalling, atherogenesis, terminal differentiation, cell cycles arrest, apoptosis, inflammation, and the regulation of eukaryotic stress responses.
- In contrast to acidic and neutral SMase, which are currently present in cells as lysosomal and membrane-bound enzymes, respectively, alkaline SMase exhibits tissue and species difference. In human beings, the alkaline SMase is found in intestinal mucosa and bile. Alkaline SMase starts to appear in the duodenum, reaches a high level in the intestine, especially in the distal part of the jejunum, and occurs in considerable amounts in the colon and rectum. This SMase presents optimal alkaline pH at 9.0, is Mg2+-independent, bile salt-dependent and trypsin-resistant.
- The pathological importance of alkaline SMase has only recently been recognized and this has prompted several studies to be carried out, mainly for the following reasons.
- First, the enzyme may be responsible for the hydrolysis of the dietary sphingomyelin occurring substantially in milk, eggs, meat and fish. Second, this enzyme may regulate cholesterol absorption. Third, the presence of alkaline SMase along the intestinal tract and its selective decrease detected in colorectal carcinoma suggests that this enzyme plays a role in intestinal carcinogenesis, since under physiological conditions, it stimulates apoptosis and protects the intestinal mucosa against carcinogenesis.
- Previous studies have also shown that, under physiological conditions, alkaline SMase is dissociated by bile salts from intestinal mucosal membrane to the lumen. However, under pathological conditions, whereby bile salt concentration is abnormally increased, the dissociation of alkaline SMase by bile salts may exceed the biosynthesis of the enzyme, resulting in a low level of activity of alkaline SMase in the mucosa, and an abnormally increased excretion of the enzyme in the faeces or in biological fluids, i.e. bile. Consequently, the excess of alkaline SMase excreted in the stools or in biological fluids over normal, basal values, may be interpreted as a valuable diagnostic marker for colon rectal carcinoma and familial adenomatous polyposis, hence; the need of a reliable assay for detecting alkaline SMase in the stools or in biological fluids of patients likely to be suffering from the aforesaid pathologies of the intestinal tract.
- In addition, some bacteria strains (e.g. Streptococcus termophilus Lactobacilli) contain high levels of SMase, and the assessment of alkaline SMase may provide a method to evaluate changes in the number of said bacteria, i.e. after a treatment with probiotics or/and probiotic-based products.
- Previous methods for assaying alkaline SMase are already known. The activity of the SMases can be determined either in vivo through cell labelled with a radioactive precursor of SM and then determining the labelling product levels or in vitro using radiolabelled SM or a chromogenic analog of SM or colored and fluorescent derivatives of neutral SM.
- These known commonly used assays are not entirely satisfactory since they are potentially very hazardous insofar as they are radioactive assays and less sensitive than a fluorometric assay.
- An object of the present invention is to provide a reliable, unexpensive assay for alkaline SMase in the stools or biological fluids of patients likely to suffer from colorectal carcinoma and familial adenomatous polyposis, or gall bladder or liver diseases, which overcomes the drawbacks of the known methods.
- A further object of the present invention is to provide an analytical kit for use in the aforesaid assay.
- Another object of the present invention is the assessment of bacterial colonization in different health conditions or following diseases or treatment with drugs or probiotics or food supplements.
- The fluorometric, indirect assay method of the present invention is grounded on the following sequence of reactions.
- Under the action of alkaline SMase, present in faeces or other biological fluids, sphingomyelin is hydrolyzed to ceramide and phosphorylcholine which, under the action of alkaline phosphatase, is hydrolyzed yelding choline. In the presence of choline oxidase, choline produces hydrogen peroxide (H2O2).
- This latter compound, in the presence of horse-radish peroxidase, is caused to react with 10-acetyl-3.7-dihidroxyphenoxazine, a sensitive fluorogenic probe for H2O2 (hereinbelow referred to as “Amplex Red Reagent”) yelding the highly fluorescent compound resorufin. Fluorescence is measured with a fluorocount microplate fluorometer using excitation at 530-560 nm and fluorescence detection at 590 nm.
- Based on the aforesaid reaction sequence and fluorescence detection means, the assay method of the present invention for assaying alcaline SMase comprises the following steps which refers to stools. However, it will be apparent to a person skilled in the art that this method can be easily applied also to biological fluids such as bile with appropriate routine variations,
- 1) collecting a sample of a patient's stools and drying it up;
- 2) weighing about 3-4 grams of the dried up sample and suspending it in 20 ml of a homogenization buffer containing 0.25 M sucrose, 0.15 M KCl, 50 mM KH2PO4, pH 7.4;
- 3) centrifuging the sample at 4000 rpm at +4° C. for 60 min;
- 4) recovering the supernatant and centrifuging again for 15 min. at 4000 rpm at +4° C.;
- 5) measuring protein content in supernatant with the Pierce Protein Assay with bovine serum albumine as standard using for each sample a range of protein concentration between 32 mg/ml and 40 mg/ml and pipetting 25 μl of each sample into well;
- 6) adding to each 25 μl sample 65 μL of assay buffer containing 50 mM Tris/HCl, 2 mM EDTA, 0.15 M NaCl pH 9.0 and 10 μl of 29 μM sphingomyelin and in assay buffer adding bile salts (TC, TDC, GC, GCDC) in the concentration of 3 mM;
- 7) incubating at 37° C. for 1 hr;
- 8) pipetting 100 μl of each standard (see below) and 10 μl of sphingomyelin (29 μM), incubating for 1 hr at 37° C. as the samples;
- 9) after 1 hour, adding 100 μl of reaction buffer containing 50 mM Tris/HCl pH 7.4, 10 mM β-glycerophosphate, 750 μM ATP, 5 mM EDTA, 5 mM EGTA, 100 μM Amplex Red, 8 U/ml alkaline phosphatase, 0.2 U/ml choline oxidase, 2 U/ml horseradish peroxidase;
- 10) incubating the reactions for 1 hour or longer at 37° C., protected from light;
- 11) measuring the fluorescence in a fluorescence microplate reader using excitation in the range of 530-560 nm and emission detection at 590 nm;
- 12) for each point, correcting for background fluorescence by subtracting the values derived from the no-sphingomyelinase control.
- The invention also relates to a kit for detecting alkaline sphingomyelinase in a patient's stools or biological fluids according to the previously disclosed method, which comprises test tubes separately containing samples of the following reagents:
- a) sphingomyelin to be hydrolized by alkaline sphingomyelinase present in the stools or biological fluids, to give phosphorylcholine;
- b) alkaline phosphatase for catalyzing the hydrolysis of phosphorylcholine to choline;
- c) choline oxidase for oxidizing choline to hydrogen peroxide;
- d) horse-radish peroxidase for assisting reaction of hydrogen peroxide with
- e) Ampler Red Reagent (10-acetyl-3,7-dihydroxyphenoxazine) to give the fluorescent compound resorufin whose fluorescence is a marker of the alkaline SMase present in the stools or biological fluids; and
- f) lyophilized bacterial sphingomyelinase for use as standard concentrate.
- For the analytical method of the present invention to be suitably carried out, in addition to the aforesaid kit components, the following further materials and equipments are required:
- Sucrose;
- Potassium chloride (KCl);
- Potassium phosphate, monobasic (KH2PO4);
- Trizma base;
- EDTA;
- Sodium chloride;
- Taurocholate (TC);
- Taurodeoxycholate (TDC);
- Glycocholate (GC);
- Glycochenodeoxycholate (GCDC);
- β-glycerophosphate;
- ATP disodium salt;
- EGTA;
- BCA Protein Assay Reagent;
- Bovine serum albumine;
- A refrigerated centrifuge;
- A microplate reader capable of measurement at 550-562 nm, and
- A fluorocount microplate fluorometer.
- In order to accomplish the quantification of SMase activity, the following measures should be taken.
- The kit is supplied with a standard preparation of SMase, it consists of bacterial extract containing a type of SMase that works at pH 9. The following operations should be performed.
- Generate a SMase calibration curve: dilute the standard concentrate to make serial dilutions.
- Reconstitute the SMase standard with 1 ml of assay buffer (pH 9.0); this reconstitution produces a stock solution of 96 mU/ml.
- Pipette 0.500 ml of assay buffer into each tube. Use the stock solution to produce a dilution series. Mix each tube thoroughly before the next transfer. The undiluted standard serves as the high standard (96 mU/ml), and the standard curve will contain the following concentrations (mU/ml): 96-48-24-12-6-3. Buffer serves as the zero standard (0 mU/ml).
- In
FIG. 1 the standard curve is shown for demonstration only. A standard curve should be generated for each set of samples assayed. - Average the duplicate readings for each standard and sample and subtract the average zero standard fluorescence.
- Plot the fluorescence for the standards versus the activity (mU/ml) of the standards and draw the best curve. To determine the SMase activity of each sample, first find the fluorescence value on the y-axis and extend a horizontal line to the standard curve. At the point of intersection, extend a vertical line to the x-axis and read the corresponding SMase activity.
- The described method is able to assay SMase activity in vitro; it has been developed with the intent to detect alkaline SMase in an organic sample.
- To assay specifically the alkaline SMase the method uses conditions that detect the acid and neutral SMases activity. In fact:
-
- the homogenization buffer is at neutral pH, but it have not protease and phosphatase inhibitors to exclude the neutral SMase since the latter is sensitive to activities of proteases and phosphatases and is consequently inhibited by these enzymes;
- in the homogenization buffer the MgCl2 is absent to block the activity of Mg dependent neutral SMase;
- the reaction buffer contains β-glycerophosphate and ATP to preclude acid SMase moreover activity at neutral pH, in this buffer EDTA and EGTA are present in high concentration to inhibit neutral SMase.
Claims (9)
1. A method for detecting alkaline sphingomyelinase in a patient's stools, which comprises the following steps:
1) collecting a sample of a patient's stools and drying it up;
2) weighing about 3-4 grams of the dried up sample and suspending it in 20 ml of a homogenization buffer containing 0.25 M sucrose, 0.15 M KC 1, 50 mM KH2PO4 pH 7.4;
3) centrifuging the sample at 4000 rpm at +4° C. for 60 min;
4) recovering the supernatant and centrifuging again for 15 mm. at 4000 rpm at +4° C.;
5) measuring protein content in supernatant with the Pierce Protein Assay with bovine serum albumine as standard using for each sample a range of protein concentration between 32 mg/ml and 40 mg/ml and pipetting 25 μl of each sample into well;
6) adding to each 25 μl sample 65 μl of assay buffer containing 50 mM Tris/HCl, 2 mM EDTA, 0.15 M NaCl pH 9.0 and 10 μl of 29 μM sphingomyelin and in assay buffer adding bile salts (TC, TDC, GC, GCDC) in the concentration of 3 mM;
7) incubating at 37° C. for 1 hr;
8) pipetting 100 μl of each standard lyophilized bacterial sphingomyelinase and 10 μl of sphingomyelin (29 μM), incubating for 1 hr at 37° C. as the samples;
9) after 1 hour, adding 100 μl of reaction buffer containing 50 mM Tris/HCl pH 7.4, 10 mM β-glycerophosphate, 750 μM ATP, 5 mM EDTA, 5 mM EGTA, 100 μM Amplex Red, 8 U/ml alkaline phosphatase, 0.2 U/ml choline oxidase, 2 U/ml horseradish peroxidase;
10) incubating the reactions for 1 hour or longer at 37° C., protected from light;
11) measuring the fluorescence in a fluorescence microplate reader using excitation in the range of 530-560 nm and emission detection at 590 nm;
12) for each point, correcting for background fluorescence by subtracting the values derived from the no-sphingomyelinase control.
2. The method of claim 1 , applied to biological fluids.
3. A kit for detecting alkaline sphingomyelinase in a patient's stools or biological fluid which comprises test tubes separately containing samples of the following reagents:
a) sphingomyelin to be hydrolized by alkaline sphingomyelinase present in the stools or biological fluids, to give phosphorylcholine;
b) alkaline phosphatase for catalyzing the hydrolysis of phosphorycholine to choline;
c) choline oxidase for oxidizing choline to hydrogen peroxide;
d) horse-radish peroxidase for assisting reaction of hydrogen peroxide with
e) Ampler Red Reagent (10-acetyl-3,7-dihydroxyphenoxazine) to give the fluorescent compound resorufin whose fluorescence is a marker of the alkaline SMase present in the stools or biological fluids; and
f) lyophilized bacterial sphingomyelinase for use as standard concentrate.
4. A method for detecting alkaline sphingomyelinase in a biological material from a patient, comprising the steps of
1) collecting a sample of the biological material;
2) suspending the sample in an homogenization buffer containing 0.24-0.26 M sucrose, 0.14-0.16 M KCl, 45-55 mM KH2PO4 adjusted to about pH 7.4;
3) centrifuging the sample at least once and recovering the supernatant;
4) measuring the protein content in supernatant;
5) adding to a sample of the supernatant an assay buffer containing 44-55 mM Tris/HCl, 1.9-2.2 mM EDTA, 0.14-0.16 M NaCl pH 8.9-9.1, 28-30 μM sphingomyelin and an assay buffer containing bile salts (TC, TDC, GC, GCDC) at a concentration of 2.9-3.1 mM;
6) incubating the assay mixture at about 37° C. for about 1 hr;
7) mixing a sample from step 6) with 28-31 μM sphingomyelin, and incubating for about 1 hr at about 37° C.;
8) adding reaction buffer containing 45-55 mM Tris/HCl pH 7.3-7.5, 9-11 mM β-glycerophosphate, 745-755 μM ATP, 4-6 mM EDTA, 4-6 mM EGTA, 95-105 μM Amplex Red reagent, 7-9 U/ml alkaline phosphatase, 0.1-0.3 U/ml choline oxidase and 1.5-2.5 U/ml horseradish peroxidase;
9) incubating the reaction mixture for at least 1 hour at about 37° C., protected from light;
10) measuring the fluorescence using excitation in the range 530-560 and emission detection at about 590 nm.
5. A method as claimed in claim 4 , wherein, for each sample, the fluorescence reading is corrected for background fluorescence by subtracting the values derived from a no-sphingomyelinase control.
6. A method as claimed in claim 1 or 5, wherein the protein content is measured by the Pierce Peotein Assay.
7. A kit for detecting alkaline sphingomyelinase in a biological sample obtained from a patient comprising:
a) sphingomyelin
b) alkaline phosphatase,
c) choline oxidase,
d) horseradish peroxidase,
e) Amplar Red reagent,
f) lyophilized bacterial sphingomyelinase.
8. A method of detecting alkaline sphingomyelinase substantially as described herein with reference to the figure.
9. A kit for detecting alkaline sphingomyelinase substantially as described herein with reference to the figure.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/359,619 US7211410B2 (en) | 2001-12-21 | 2006-02-23 | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method |
US11/712,417 US7323317B2 (en) | 2001-12-21 | 2007-03-01 | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE011100 | 2001-12-21 | ||
IE20011100A IE20011100A1 (en) | 2001-12-21 | 2001-12-21 | Analytical Method for Detecting Alkaline Sphingomyelinase and Kit for Use in Such Method |
PCT/IT2002/000811 WO2003056031A2 (en) | 2001-12-21 | 2002-12-19 | Method and kit for detecting alkaline sphingomyelinase |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2002/000811 Continuation WO2003056031A2 (en) | 2001-12-21 | 2002-12-19 | Method and kit for detecting alkaline sphingomyelinase |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/359,619 Division US7211410B2 (en) | 2001-12-21 | 2006-02-23 | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050118152A1 true US20050118152A1 (en) | 2005-06-02 |
Family
ID=11042874
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/499,336 Abandoned US20050118152A1 (en) | 2001-12-21 | 2002-12-19 | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method |
US11/359,619 Expired - Fee Related US7211410B2 (en) | 2001-12-21 | 2006-02-23 | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method |
US11/712,417 Expired - Fee Related US7323317B2 (en) | 2001-12-21 | 2007-03-01 | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/359,619 Expired - Fee Related US7211410B2 (en) | 2001-12-21 | 2006-02-23 | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method |
US11/712,417 Expired - Fee Related US7323317B2 (en) | 2001-12-21 | 2007-03-01 | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method |
Country Status (29)
Country | Link |
---|---|
US (3) | US20050118152A1 (en) |
EP (1) | EP1456405B1 (en) |
JP (2) | JP2005512601A (en) |
KR (1) | KR101002068B1 (en) |
CN (1) | CN101126716A (en) |
AR (1) | AR038037A1 (en) |
AT (1) | ATE408707T1 (en) |
AU (1) | AU2002367123B2 (en) |
BR (1) | BRPI0215045B1 (en) |
CA (1) | CA2469796C (en) |
CY (1) | CY1108512T1 (en) |
DE (1) | DE60228993D1 (en) |
DK (1) | DK1456405T3 (en) |
EG (1) | EG25804A (en) |
ES (1) | ES2312666T3 (en) |
HK (1) | HK1075069A1 (en) |
HR (1) | HRP20040632B1 (en) |
HU (1) | HU228812B1 (en) |
IE (1) | IE20011100A1 (en) |
IL (2) | IL162513A0 (en) |
MX (1) | MXPA04005919A (en) |
NO (1) | NO331806B1 (en) |
NZ (1) | NZ533806A (en) |
PL (1) | PL207876B1 (en) |
PT (1) | PT1456405E (en) |
RU (1) | RU2316002C2 (en) |
SI (1) | SI1456405T1 (en) |
WO (1) | WO2003056031A2 (en) |
ZA (1) | ZA200405762B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070141041A1 (en) * | 2005-12-15 | 2007-06-21 | Chemgen Corporation | Enzymes for reduced immunological stress |
CN103760348A (en) * | 2014-02-11 | 2014-04-30 | 苏州博源医疗科技有限公司 | Glycocholic acid immunodetection reagent and preparing method and detecting method thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE20011100A1 (en) | 2001-12-21 | 2003-07-09 | Vsl Pharma Ltd | Analytical Method for Detecting Alkaline Sphingomyelinase and Kit for Use in Such Method |
CN104614371A (en) * | 2015-02-15 | 2015-05-13 | 史春龙 | Method for detecting biochemical indexes of excrement in toilet and detection equipment using same |
CN117630364B (en) * | 2023-12-05 | 2024-07-30 | 临沂大学 | A method for detecting trace amounts of aflatoxin B1 using a dual enzyme immunofluorescence system |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265179B1 (en) * | 2000-02-01 | 2001-07-24 | Molecular Probes, Inc. | Detection of phosphate using coupled enzymatic reactions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1311495B1 (en) * | 1999-06-09 | 2002-03-13 | Mendes S U R L | COMPOSITION INCLUDING ALKALINE SPHYNOMYELINASE, USABLE AS A DIETARY PRODUCT, FOOD SUPPLEMENT OR MEDICATION. |
IE20011100A1 (en) | 2001-12-21 | 2003-07-09 | Vsl Pharma Ltd | Analytical Method for Detecting Alkaline Sphingomyelinase and Kit for Use in Such Method |
-
2001
- 2001-12-21 IE IE20011100A patent/IE20011100A1/en not_active IP Right Cessation
-
2002
- 2002-12-19 SI SI200230740T patent/SI1456405T1/en unknown
- 2002-12-19 DE DE60228993T patent/DE60228993D1/en not_active Expired - Lifetime
- 2002-12-19 MX MXPA04005919A patent/MXPA04005919A/en active IP Right Grant
- 2002-12-19 CA CA2469796A patent/CA2469796C/en not_active Expired - Fee Related
- 2002-12-19 NZ NZ533806A patent/NZ533806A/en not_active IP Right Cessation
- 2002-12-19 DK DK02805875T patent/DK1456405T3/en active
- 2002-12-19 HU HU0402542A patent/HU228812B1/en not_active IP Right Cessation
- 2002-12-19 AU AU2002367123A patent/AU2002367123B2/en not_active Ceased
- 2002-12-19 BR BRPI0215045A patent/BRPI0215045B1/en not_active IP Right Cessation
- 2002-12-19 IL IL16251302A patent/IL162513A0/en unknown
- 2002-12-19 JP JP2003556548A patent/JP2005512601A/en active Pending
- 2002-12-19 WO PCT/IT2002/000811 patent/WO2003056031A2/en active IP Right Grant
- 2002-12-19 PL PL374085A patent/PL207876B1/en unknown
- 2002-12-19 EP EP02805875A patent/EP1456405B1/en not_active Expired - Lifetime
- 2002-12-19 KR KR1020047008886A patent/KR101002068B1/en not_active Expired - Fee Related
- 2002-12-19 PT PT2805875T patent/PT1456405E/en unknown
- 2002-12-19 AR ARP020104993A patent/AR038037A1/en active IP Right Grant
- 2002-12-19 CN CNA200710147169XA patent/CN101126716A/en active Pending
- 2002-12-19 US US10/499,336 patent/US20050118152A1/en not_active Abandoned
- 2002-12-19 RU RU2004122426/15A patent/RU2316002C2/en not_active IP Right Cessation
- 2002-12-19 ES ES02805875T patent/ES2312666T3/en not_active Expired - Lifetime
- 2002-12-19 AT AT02805875T patent/ATE408707T1/en active
- 2002-12-21 EG EG2002121379A patent/EG25804A/en active
-
2004
- 2004-06-14 IL IL162513A patent/IL162513A/en not_active IP Right Cessation
- 2004-07-12 HR HRP20040632AA patent/HRP20040632B1/en not_active IP Right Cessation
- 2004-07-13 NO NO20042992A patent/NO331806B1/en not_active IP Right Cessation
- 2004-07-20 ZA ZA200405762A patent/ZA200405762B/en unknown
-
2005
- 2005-08-22 HK HK05107338.1A patent/HK1075069A1/en not_active IP Right Cessation
-
2006
- 2006-02-23 US US11/359,619 patent/US7211410B2/en not_active Expired - Fee Related
-
2007
- 2007-03-01 US US11/712,417 patent/US7323317B2/en not_active Expired - Fee Related
-
2008
- 2008-11-13 CY CY20081101308T patent/CY1108512T1/en unknown
-
2009
- 2009-04-22 JP JP2009104135A patent/JP5009332B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6265179B1 (en) * | 2000-02-01 | 2001-07-24 | Molecular Probes, Inc. | Detection of phosphate using coupled enzymatic reactions |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070141041A1 (en) * | 2005-12-15 | 2007-06-21 | Chemgen Corporation | Enzymes for reduced immunological stress |
US7914782B2 (en) | 2005-12-15 | 2011-03-29 | Chemgen Corporation | Enzymes for reduced immunological stress |
EP2263685A3 (en) * | 2005-12-15 | 2011-04-06 | Chemgen Corporation | Alkaline phosphatase for reducing immunological stress |
US20110171345A1 (en) * | 2005-12-15 | 2011-07-14 | Chemgen Corporation | Enzymes for reduced immunological stress |
US20110171344A1 (en) * | 2005-12-15 | 2011-07-14 | Chemgen Corporation | Enzymes for reduced immunological stress |
US20110177195A1 (en) * | 2005-12-15 | 2011-07-21 | Chemgen Corporation | Enzymes for reduced immunological stress |
US8778648B2 (en) | 2005-12-15 | 2014-07-15 | Eli Lilly And Company | Enzymes for reduced immunological stress |
CN103760348A (en) * | 2014-02-11 | 2014-04-30 | 苏州博源医疗科技有限公司 | Glycocholic acid immunodetection reagent and preparing method and detecting method thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7211410B2 (en) | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method | |
CA2722444C (en) | Acetaminophen assay | |
JP2009195239A6 (en) | Analytical method for detecting alkaline sphingomyelinase and kit for use in such method | |
Beltrán-Ortiz et al. | Standardization of a colorimetric technique for determination of enzymatic activity of diamine oxidase (DAO) and its application in patients with clinical diagnosis of histamine intolerance | |
JP6360848B2 (en) | Rapid mass screening test for lysosomal disease 3 responsible enzyme | |
JP6989872B2 (en) | Simultaneous screening test method for 6 diseases of inborn errors of metabolism | |
CN100491540C (en) | Kit for detecting alkaline sphingomyelinase | |
US7374902B2 (en) | Enzyme cycling based assays for alpha-methylacyl-CoA racemase | |
JP4043053B2 (en) | Method for detecting procarboxypeptidase A and carboxypeptidase A levels in biological fluids | |
CN106556595B (en) | A kind of Picric kinetic method detection kit of strong antijamming capability | |
Lee et al. | An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay | |
AU2005295677A1 (en) | Enzyme cycling based assays for alpha-methylacyl-CoA racemase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VSL PHARMACEUTICALS, INC., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DE SIMONE, CLAUDIO;REEL/FRAME:016158/0849 Effective date: 20040524 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |